TNF inhibitor

Many practicing, and retired, rheumatologists will recall a time when we only had TNFi for the treatment of SpA. These drugs changed the landscape of disease and for the first time, we felt we had…

The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid…

There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade. Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. There are three areas that always draw my attention each conference and…

New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a…